Stephens Investment Management Group LLC acquired a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 612,470 shares of the biopharmaceutical company's stock, valued at approximately $4,998,000. Stephens Investment Management Group LLC owned about 0.20% of Amicus Therapeutics as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC lifted its stake in shares of Amicus Therapeutics by 53.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 24,530 shares of the biopharmaceutical company's stock valued at $195,000 after purchasing an additional 8,567 shares during the period. Intech Investment Management LLC lifted its stake in shares of Amicus Therapeutics by 59.7% in the 4th quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company's stock valued at $1,175,000 after purchasing an additional 46,633 shares during the period. Norges Bank acquired a new position in shares of Amicus Therapeutics in the 4th quarter valued at $29,033,000. Renaissance Technologies LLC lifted its stake in shares of Amicus Therapeutics by 174.1% in the 4th quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company's stock valued at $19,863,000 after purchasing an additional 1,339,316 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Amicus Therapeutics by 35.7% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 302,536 shares of the biopharmaceutical company's stock valued at $2,850,000 after purchasing an additional 79,602 shares during the period.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on the stock. The Goldman Sachs Group reduced their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Wall Street Zen lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday. Finally, UBS Group lifted their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.22.
Check Out Our Latest Stock Report on FOLD
Amicus Therapeutics Stock Performance
Shares of Amicus Therapeutics stock traded up $0.22 during trading on Thursday, reaching $6.29. The company's stock had a trading volume of 5,224,185 shares, compared to its average volume of 3,239,513. The company has a current ratio of 3.34, a quick ratio of 2.47 and a debt-to-equity ratio of 2.02. The firm has a market cap of $1.94 billion, a PE ratio of -69.88 and a beta of 0.51. The company has a 50-day moving average price of $6.07 and a two-hundred day moving average price of $7.69. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $12.65.
About Amicus Therapeutics
(
Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Recommended Stories
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
